<DOC>
	<DOCNO>NCT01432730</DOCNO>
	<brief_summary>This randomise , double-blind , placebo-controlled , crossover , single centre study AF-219 subject idiopathic chronic cough design evaluate effectiveness AF-219 reducing daytime objective cough frequency .</brief_summary>
	<brief_title>A Study Assess Efficacy AF-219 , P2X3 Receptor Antagonist , Subjects With Chronic Cough</brief_title>
	<detailed_description />
	<mesh_term>Cough</mesh_term>
	<criteria>History cough 8 week Normal chest radiograph Idiopathic treatment resistant cough ( idiopathic define cough objective evidence underlie trigger determine investigation cough unresponsive 8 week target treatment identify underlying trigger include reflux disease , asthma postnasal drip [ treatmentresistant ] ) . Current smoker Individuals give smoking within past 6 month , &gt; 20 packyear smoke history Treatment ACEinhibitor potential cause subject 's cough , require treatment ACEinhibitor study within 4 week prior Day 0 FEV1/FVC &lt; 60 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>